SNS-032

N/A

Report date: 2026/01/06 18:01:01
NME

Base Information

Drug NameSNS-032
Drug Alias NameBMS-387032SNS-032
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsCyclin-dependent kinase 2 inhibitorsCyclin-dependent kinase 7 inhibitors
TargetsCyclin-dependent kinase 9Cyclin-dependent kinase 2Cyclin-dependent kinase 7
Therapy Area/IndicationsMultiple MyelomaLymphoma, Mantle-CellLymphoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSunesis Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, Mantle-CellLymphoma +[5] 

Other Information

ATC CodeN/A
Related LinksN/A